Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.

Pietro Invernizzi,Marco Carbone,David Jones,Cynthia Levy,Nicola Little,Philippe Wiesel,Frederik Nevens

Liver international : official journal of the International Association for the Study of the Liver（2023）

引用 1|浏览14

暂无评分

摘要

The primary endpoint was not met. However, the secondary endpoints provide preliminary evidence for potential anti-cholestatic and anti-fibrotic effects in PBC, supporting the further evaluation of setanaxib in a future phase 2b/3 trial.

查看译文

关键词

cholestasis, fibrosis, NADPH oxidase 1, 4 inhibitor, primary biliary cholangitis, setanaxib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要